October 21, 2011
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Taiwan NDA Approval of Bendamustine Hydrochloride (SyB L-0501)
TOKYO, Japan, October 21, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President &CEO: Fuminori Yoshida, “SymBio”) announced that InnoPharmax Inc. (Headquarters: Taipei City, Taiwan,“InnoPharmax”) received approval of its New Drug Application (NDA) for bendamustine HCl (SyB L-0501)
from the Taiwan Food and Drug Administration (TFDA) on October 18, 2011 for the treatment of patients withindolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. SyB L-0501 will be marketed under thetrade name Innomustine® in Taiwan. A License Agreement was concluded between the two companies inMarch, 2008, in which SymBio granted InnoPharmax the exclusive right to develop and market the drug inTaiwan.
In Japan, SymBio received market approval of TREAKISYM® (SyB L-0501) in October, 2010 for
the treatment of patients with refractory/relapsed low-grade non-Hodgkin’s lymphoma and mantle celllymphoma. Sales of TREAKISYM® in Japan continue to gain momentum since its launch in December, 2010,by SymBio’s business partner, Eisai Co., Ltd. In other Asian markets, SyB L-0501 has been approved in Hong
Kong (December, 2009) and Singapore (January, 2010) for the treatment of patients with indolent
non-Hodgkin's lymphoma and chronic lymphocytic leukemia, and in South Korea (May, 2011) for thetreatment of patients with chronic lymphocytic leukemia and multiple myeloma.
Aspiring to be a leading oncology specialty Pharma in Asia Pacific, SymBio's business in key Asian markets
continues to expand as it nimbly develops and commercializes SyB L-0501 in the hematology space toaddress the underserved medical needs of patients.

The product launch in Taiwan has been included in SymBio’s financial forecast for FY 2011.

[Please see the following for further information on bendamustine hydrochloride and SymBio][Contact]
Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

Note to Editors

1. About Bendamustine Hydrochloride (SyB L-0501))
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm, and iscurrently marketed in Germany under the brand name “Ribomustin®” as a treatment for non-Hodgkin’s
lymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market
authorization in a number of EU countries for bendamustine under the brand name “Levact®.” In the UnitedStates, the drug has been approved by the U.S. Food and Drug Administration and is marketed asTREANDA® for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's
lymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas DeutschlandGmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize
bendamustine in Japan (December, 2005), followed by signature of a second license agreement for theexclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).
2. About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochlorideIndications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused
intravenously over 60 minutes on Days 1 and 2 of repeated 21-day cycles. The dose may
be reduced as deemed appropriate according to the patient’s condition.
3. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously
served concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currentlyTakeda Bio Development Center Limited). The company’s underlying corporate mission is “delivering
hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacificdedicated to addressing underserved medical needs in the areas of oncology, hematology andautoimmune disease.